Australia’s Menopause Guidance Puts Symptom Evidence First

On October 17, 2026, ABC News reported that the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) had issued updated clinical guidance for managing menopausal symptoms.

Existing treatment choices receive clearer guidance

ABC’s report describes a clarification of treatment choices rather than a previous medical protocol being overturned. Menopausal hormone therapy (MHT) remains part of a discussion that includes other medicines and approaches such as acupuncture and hypnosis. The update organises those choices through evidence grades and recommendations for particular symptoms.

That is a more precise change than a blanket instruction to choose hormones. It gives comparisons between menopause care approaches a clearer foundation while leaving individual treatment decisions with a woman and her qualified clinician.

The guidance connects treatment evidence with specific symptoms

ABC’s account identifies several findings and recommendations that matter for women navigating treatment information. The central distinction is between evidence for a particular symptom and broader claims about what a treatment might do for midlife health.

• The scope centres on defined symptom groups. The guidance addresses women aged 40 and older. It focuses on vasomotor symptoms such as hot flashes and night sweats, plus genitourinary symptoms such as vaginal dryness and frequent urination. ABC describes menopause as occurring 12 months after a woman’s final menstrual period, but the practical focus of this guidance is the symptoms being discussed rather than a complete account of every change around that milestone.
• Treatment options are compared through evidence grades. According to ABC, the guidelines assess options including MHT, acupuncture and hypnosis, with supporting evidence graded from very low to high. Inclusion in that comparison does not mean that every option works equally well or has equally strong support. For a treatment discussion, the useful question is what evidence supports an option for the symptom that matters to the woman seeking care.
• MHT receives a clearer place in treatment comparisons. ABC reports that the guidance clarifies when MHT should be preferred over other medicines. Its article does not identify those circumstances or the medicines being compared, and it does not reproduce the full guideline or detailed evidence tables. That reporting boundary matters: the announcement supports a clinician-led comparison, not a universal ranking that readers can apply to their own medical history without a fuller assessment.
• Women using MHT are advised to have an annual check-up. The reported recommendation is for an annual review with a healthcare provider. It applies to MHT users rather than establishing an annual menopause-specific examination for everyone. A regular review provides a point for discussing treatment and current concerns with a clinician; readers can use questions about the goals of hormone therapy as background for that conversation rather than as a substitute for personal care.
• A breast cancer history is addressed without a blanket treatment rule. ABC reports that vaginal estrogen may be offered as an option for some women with a history of breast cancer. This is a possible discussion point, not a declaration that it is suitable for everyone with that history. For women experiencing genitourinary symptoms, the practical implication is that symptom relief deserves a qualified clinical conversation that takes their medical history into account.
• Exercise and weight loss are not established as reliable stand-alone relief for hot flashes or night sweats. According to ABC’s account, evidence is insufficient to conclude that physical activity or weight loss alone alleviates those symptoms. This finding concerns symptom relief, not whether movement or weight management has any other health relevance. The distinction separates broader health goals from the question of what reliably helps a particular symptom, without making body size or an exercise routine the measure of whether someone deserves further care.
• The sleep claim for hypnosis also has an evidence gap. ABC reports insufficient evidence that hypnosis improves sleep. That statement concerns a specific outcome and should be read at that level. A treatment’s appearance in a guideline comparison is not enough to support every claim made about it; evidence about sleep needs to be distinguished from evidence about another symptom or outcome.
• Several substantial midlife concerns sit outside this guideline’s remit. The reported scope excludes bone density and joint discomfort. It also excludes libido, depression and anxiety. Those exclusions describe the questions this guidance addresses, not the importance of the concerns themselves; they remain appropriate subjects for separate clinical discussion rather than matters to dismiss because they are absent from this document.
• Clinicians are encouraged to ask about troublesome symptoms. ABC reports particular attention to First Nations, Māori and Pacific Islander women and others who may face barriers to treatment. This recommendation places responsibility on the clinical conversation rather than expecting every woman to arrive with the right terminology or a preferred prescription. The starting point is what is troubling her and how it affects daily life.
• This guidance is distinct from another planned Australian guideline project. ABC reports that the Australian government had allocated funding for separate perimenopause and menopause guidelines expected the following year. RANZCOG was reported to be contributing to ongoing updates as research emerges. The current announcement is therefore guidance from the professional college, not the publication of those separate government-funded guidelines.

A useful consultation starts with the woman’s priorities

The practical message is not that women need to arrive at an appointment having selected a treatment. The guidance encourages clinicians to ask about symptoms that trouble them. Describing the effect on sleep, comfort or usual activities gives that discussion a concrete starting point.

A conversation can then connect the concern with the relevant options. Questions might address which approaches fit the symptom, what evidence supports them and whether MHT is appropriate in the person’s circumstances. For someone already using MHT, the reported annual review recommendation is another topic to raise with their healthcare provider.

This keeps the discussion anchored in a woman’s experience without turning an appointment into a demand for one intervention. It also leaves room for concerns beyond the guideline’s remit. A focused symptom discussion and a broader health conversation do not have to compete for legitimacy.

The useful preparation is therefore descriptive rather than diagnostic: what is happening and what is most disruptive. The guideline provides a framework for discussing treatment evidence. It does not require a woman to decide in advance whether every change in her body has a hormonal explanation.

The guideline chair puts evidence ahead of noise

Catriona Melville, chair of the guideline development group, told ABC that the aim was to “cut through the noise” with evidence-based recommendations for clinicians to discuss with patients. That wording captures the purpose of a framework that distinguishes options by their supporting evidence rather than by the volume of attention they receive.

The wider clinical perspective in ABC’s report comes from Magdalena Simonis. She is a general practitioner and women’s health specialist at the University of Melbourne who was not involved in developing the guidelines. Simonis cautioned that women do not all experience the same symptoms or intensity and argued for considering the whole person.

She also suggested that menopause-related appointments can provide an opportunity to discuss cholesterol and bone health. Lifestyle and family cancer history were other topics she identified, alongside breast and cervical screening. These were her broader clinical observations rather than an expansion of the guideline’s formal scope.

Sarah White, CEO of Jean Hailes for Women’s Health, was also not involved in developing the guidance. She told ABC that the recommendations could help health professionals give consistent advice amid online misinformation. The editorial distinction is useful: greater consistency in explaining evidence need not mean identical treatment decisions for every woman.

Clearer evidence should support more focused care

This guidance should move clinical practice toward clearer symptom-specific treatment discussions while keeping a woman’s wider health needs on the agenda.

How Refemina helps

A symptom guideline should not become a reason to market a hormone, supplement or weight-loss programme for every midlife concern. Refemina addresses that problem through evidence-aware editorial coverage that places treatment claims beside women’s wider health priorities, helping readers understand changing bodies without reducing this stage of life to a purchase.

Explore Resources

Sources

1. Australia has new guidelines for managing menopausal symptoms